Xinyue Lu1, Jia Lu2,3, Felicia Zhang4, Abram L Wagner4, Liping Zhang2,3, Kewen Mei2,3, Baichu Guan1, Yihan Lu1. 1. Department of Epidemiology, Ministry of Education Key Laboratory of Public Health Safety, Fudan University School of Public Health, Shanghai, China. 2. Department of Immunization Planning, Minhang District Center for Disease Control and Prevention, Shanghai, China. 3. Minhang Branch, Fudan University School of Public Health, Shanghai, China. 4. Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Herpes zoster vaccine (HZV) has been available in China's mainland since June 2020. This study estimated willingness to receive HZV to characterize factors that may influence vaccination willingness. METHODS: We conducted a face-to-face questionnaire survey in adults aged 50-69 years in 13 communities in Shanghai in late 2020. We explored the relationship between vaccination willingness and independent factors including demographic factors, medical history, knowledge of herpes zoster and HZV, and vaccine hesitancy. Outcomes included participants' willingness to vaccinate themselves, their partners, and their parents, under both the current payment scenario (self-payment) and a hypothetical scenario (payment by basic medical insurance). RESULTS: A total of 1672 respondents aged 50-69 years were included in this study. The proportion of respondents willing to get vaccinated was 16.57% for themselves, 13.88% for their partners, and 8.49% for their parents. If the vaccine was covered under insurance, these numbers increased to 72.25%, 62.50%, and 29.96%, respectively. Younger age, female gender, higher income, higher educational level, local residents, and lower vaccine hesitancy were associated with increased willingness to vaccinate. Knowledge of herpes zoster and HZV positively influenced the willingness in the hypothetical payment scenario. CONCLUSION: We determined a very low willingness to vaccinate HZV in adults aged 50-69 years in a Chinese metropolis. Decreasing costs is important to increase coverage. Additionally, strengthening advocacy and health promotion for the vaccine will be particularly important, especially for groups with certain underlying diseases.
BACKGROUND: Herpes zoster vaccine (HZV) has been available in China's mainland since June 2020. This study estimated willingness to receive HZV to characterize factors that may influence vaccination willingness. METHODS: We conducted a face-to-face questionnaire survey in adults aged 50-69 years in 13 communities in Shanghai in late 2020. We explored the relationship between vaccination willingness and independent factors including demographic factors, medical history, knowledge of herpes zoster and HZV, and vaccine hesitancy. Outcomes included participants' willingness to vaccinate themselves, their partners, and their parents, under both the current payment scenario (self-payment) and a hypothetical scenario (payment by basic medical insurance). RESULTS: A total of 1672 respondents aged 50-69 years were included in this study. The proportion of respondents willing to get vaccinated was 16.57% for themselves, 13.88% for their partners, and 8.49% for their parents. If the vaccine was covered under insurance, these numbers increased to 72.25%, 62.50%, and 29.96%, respectively. Younger age, female gender, higher income, higher educational level, local residents, and lower vaccine hesitancy were associated with increased willingness to vaccinate. Knowledge of herpes zoster and HZV positively influenced the willingness in the hypothetical payment scenario. CONCLUSION: We determined a very low willingness to vaccinate HZV in adults aged 50-69 years in a Chinese metropolis. Decreasing costs is important to increase coverage. Additionally, strengthening advocacy and health promotion for the vaccine will be particularly important, especially for groups with certain underlying diseases.
Authors: Helen S Pentikis; Mark Matson; George Atiee; Brian Boehlecke; Jeff T Hutchins; Joseph M Patti; Geoffrey W Henson; Amy Morris Journal: Antimicrob Agents Chemother Date: 2011-03-28 Impact factor: 5.191
Authors: A Cy Lam; M Y Chan; H Y Chou; S Y Ho; H L Li; C Y Lo; K F Shek; S Y To; K K Yam; I Yeung Journal: Hong Kong Med J Date: 2017-07-07 Impact factor: 2.227
Authors: Ryan R Thompson; Christina L Kong; Travis C Porco; Eric Kim; Caleb D Ebert; Nisha R Acharya Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 9.079
Authors: Walter W Williams; Peng-Jun Lu; Alissa O'Halloran; David K Kim; Lisa A Grohskopf; Tamara Pilishvili; Tami H Skoff; Noele P Nelson; Rafael Harpaz; Lauri E Markowitz; Alfonso Rodriguez-Lainz; Amy Parker Fiebelkorn Journal: MMWR Surveill Summ Date: 2017-05-05